Literature DB >> 16144502

Assessing the economic impact of chronic conditions in postmenopausal women.

Alicia C Sasser1, Maida Taylor, Howard G Birnbaum, Michael J Schoenfeld, Emily F Oster, Matthew Rousculp.   

Abstract

The ageing of the US population and the recognised importance of preventative care has led to a growing body of research regarding the morbidity and mortality associated with chronic diseases in postmenopausal women. According to the National Institute of Health, postmenopausal women have a significant increase in risk for a number of debilitating diseases, including osteoporosis, breast cancer and cardiovascular disease. In addition, recently published studies prompted patients, clinicians and payers to re-examine the risks and benefits of a well-accepted therapy to treat postmenopausal symptoms. The objective of this paper is to provide a framework for assessing the economic impact of disorders affecting postmenopausal women, with a particular focus on osteoporosis, breast cancer and cardiovascular disease. This framework considers the prevalence of these conditions, the profiles of women suffering from each of them and prevailing patterns of treatment for these disorders. Taken together, these factors are used to analyse the overall economic impact of postmenopausal disorders and to provide an expert opinion in this context.

Entities:  

Mesh:

Year:  2005        PMID: 16144502     DOI: 10.1517/14656566.6.11.1803

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  5 in total

1.  Economic return from the Women's Health Initiative estrogen plus progestin clinical trial: a modeling study.

Authors:  Joshua A Roth; Ruth Etzioni; Teresa M Waters; Mary Pettinger; Jacques E Rossouw; Garnet L Anderson; Rowan T Chlebowski; Joann E Manson; Mark Hlatky; Karen C Johnson; Scott D Ramsey
Journal:  Ann Intern Med       Date:  2014-05-06       Impact factor: 25.391

Review 2.  Efficacy and Safety of Duhuo Jisheng Decoction for Postmenopausal Osteoporosis: A Systematic Review and Meta-Analysis.

Authors:  Jinyu Li; Wei Wang; Guiyu Feng; Jian Du; Shengqian Kang; Zhe Li; Weifeng Zhu; Hongcai Shang
Journal:  Evid Based Complement Alternat Med       Date:  2020-09-15       Impact factor: 2.629

3.  Identification of aberrantly expressed long non-coding RNAs in postmenopausal osteoporosis.

Authors:  Qi Fei; Xiaodong Bai; Jisheng Lin; Hai Meng; Yong Yang; Ai Guo
Journal:  Int J Mol Med       Date:  2018-03-19       Impact factor: 4.101

4.  LncRNA SNHG1 was down-regulated after menopause and participates in postmenopausal osteoporosis.

Authors:  Shuaihao Huang; Xiaowen Zhu; Dan Xiao; Jianxiong Zhuang; Guoyan Liang; Changxiang Liang; Xiaoqing Zheng; Yuhong Ke; Yunbing Chang
Journal:  Biosci Rep       Date:  2019-11-29       Impact factor: 3.840

5.  Endochondral ossification pathway genes and postmenopausal osteoporosis: Association and specific allele related serum bone sialoprotein levels in Han Chinese.

Authors:  Yunzhi Zhang; Haiyan Liu; Chen Zhang; Tianxiao Zhang; Bo Zhang; Lu Li; Gang Chen; Dongke Fu; KunZheng Wang
Journal:  Sci Rep       Date:  2015-11-16       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.